BioInvent International
LUND, SWEDEN / ACCESSWIRE / December 20, 2021 / BioInvent International (STO:BINV)
Lund, Sweden - December 20, 2021 - BioInvent International AB ("BioInvent") (NASDAQ Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that the company will be moved to the Mid Cap segment on Nasdaq Stockholm from January 3, 2022. The change from Small Cap is a result of Nasdaq's annual review of the average market value in the Nordic market segments. The Mid-cap segment includes companies with a market capitalization between EUR 150 million and EUR 1 billion.
"The promotion of the BioInvent share to the Nasdaq Nordics Mid Cap segment further bolsters the profile of our company, and the significant progress we have made in expanding our pipeline with several candidates in clinical development," said Martin Welschof, CEO of BioInvent.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively and a fifth program just initiating clinical development. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
For further information, please contact:
Cecilia Hofvander, Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/678565/BioInvent-Moves-to-NASDAQ-Stockholms-Mid-Cap-Segment
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Innodata to Participate in Multiple Upcoming Investor Conferences15.5.2025 16:15:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / INNODATA INC. (Nasdaq:INOD), a leading data engineering company, today announced that it will participate in several upcoming investor conferences in May and June 2025. The scheduled conferences include: 22nd Annual Craig-Hallum Institutional Investor Conference May 28, 2025, Minneapolis TD Cowen 53rd Annual Technology, Media & Telecom Conference May 29, 2025, New York Stifel's Eighth Annual Boston Cross Sector Insight Conference June 4, 2025, Boston Maxim Group 2025 Virtual Tech Conference June 5, 2025, Virtual Mizuho Technology Conference 2025 June 10, 2025, New York Jack Abuhoff, CEO, and Aneesh Pendharkar, SVP of Finance and Corporate Development, will be available for one-on-one meetings with investors at each conference. Investors who wish to request a meeting with Innodata at any of these conferences should contact their representative at the sponsoring investment firm. Additionally, Jack Abuhoff will be presenting at the TD Cowen
Loar Announces Pricing of Secondary Public Offering14.5.2025 21:55:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 14, 2025 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today the pricing of a secondary underwritten public offering of 9,000,000 shares of its common stock by certain of its stockholders at $83.41 per share. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 16, 2025, subject to customary closing conditions. The selling stockholders will receive all of the proceeds from this offering. Loar is not selling any shares of common stock in this offering and will not receive any proceeds from this offering. Jefferies and Morgan Stanley are acting as lead book runners for the offering. Moelis & Company, Citigroup and RBC Capital Markets are additionally acting as book runners. Blackstone is acting as co-manager. An automatic shelf regis
Maxon Introduces New Real-Time Rendering and Cinematic Previews Solution for Architects14.5.2025 02:10:00 CEST | Press release
Maxon gives first preview of new solution with partner Vectorworks at AIA Conference on Architecture & Design 2025 BAD HOMBURG, GERMANY / ACCESS Newswire / May 14, 2025 / Maxon, maker of powerful, approachable software solutions for creators working in 2D and 3D design, motion graphics, visual effects, gaming and more, is further optimizing its cinematic rendering technology for architectural visualization (ArchViz). For decades, Maxon's technology has empowered top artists to achieve the impossible in both the real world and imaginary-from architecture, construction and product design, to mind-bending visual effects, animation and 3D sculpting. Now, that same level of excellence is being engineered specifically for architects and designers-expanding on the power of Maxon's Cinema 4D and Redshift solutions to meet the demands of real-world, real-time architecture design workflows. Seamlessly integrating with major CAD and BIM tools like Vectorworks, this new platform will allow users t
Loar Announces Launch of Secondary Public Offering13.5.2025 16:26:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 13, 2025 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today the launch of a secondary underwritten public offering of 9,000,000 shares of its common stock by certain of its stockholders. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 1,350,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Such selling stockholders will receive all of the proceeds from this offering. Loar is not selling any shares of common stock in this offering and will not receive any proceeds from this offering. Jefferies and Morgan Stanley are acting as lead book runners for the proposed offering. Blackstone is acting as co-manager. An automatic shelf registration statement (including a base prospectus) relating to this offering of common stock was filed by Loar with the Securities and Exchange Commission (the "SEC") on May 1, 2025 and became effec
Detego Global Announces Sponsorship of British Police Rugby Team for 2025 Centenary Tour of South Africa13.5.2025 12:30:00 CEST | Press release
HORSHAM, UNITED KINGDOM / ACCESS Newswire / May 13, 2025 / Following the resounding success of their sponsorship of the England Police Rugby Team's 2024 South African tour, Detego Global, the leading provider of cutting-edge digital forensics and investigative technology, is proud to announce its sponsorship of the British Police Rugby Team's 2025 centenary tour of South Africa, bringing together players from all four nations of England, Ireland, Scotland, and Wales. This new partnership strengthens a shared commitment to community engagement and global cooperation whilst marking an important occasion - the beginning of the British Police Rugby Team's centenary celebrations. Founded in 1925, the British Police Rugby Team has upheld a proud tradition of sporting excellence and service for a century. The 2025 tour of South Africa launches a year of commemorative events and fixtures, starting with two major matches, including one at the world-famous Hollywoodbets Kings Park Stadium in Dur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom